EHMT2 and Alzheimer disease: To precisely evaluate the drug effects or individual responses to the drug, instead of conventional assays with available AD markers (if any) for one-protein-at-a-time validations, our global comparison of AD mice and AD patient proteomes11 determined the impact of MS1262 inhibition of G9a on AD therapy.